News
Sep 8, 2014
CardioCell Scientific Advisory Board Chair Debates in “Strategies for Cardiovascular Repair” Didactic Science Symposium at TCT2014
WASHINGTON, D.C. – TCT2014 – Sept. 8, 2014 – CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that creates allogeneic stem-cell therapies for cardiovascular indications, announces TCT2014 debate participation by prominent cardiologist Dr. Stephen Epstein, the company’s Scientific Advisory Board chair, as well as director, translational and vascular biology research at MedStar Heart Institute and clinical professor of medicine at Georgetown University.
|
Details: |
The Transcatheter Cardiovascular Therapeutics (TCT) Meeting of the Cardiovascular Research Foundation showcases the latest advances in current therapies and clinical research. Programming includes “Didactic Science Symposia” that convenes opinion leaders in a “Discovery and Debate” format. For TCT’s “Strategies for Cardiovascular Repair” symposium, Dr. Epstein shares perspectives on “Enhancement of MSC Function by Chronic Exposure to Hypoxia” and leverages data from CardioCell, whose novel method of growing mesenchymal stem cells under chronic hypoxic conditions is yielding promising clinical-trial data from chronic heart failure and acute myocardial infarction studies. |
|
When: |
Mon., Sept. 15, 2014, from 2-6 p.m. Eastern time |
|
Where: |
TCT2014 |
About CardioCell LLC
Founded in San Diego, California, in 2013, CardioCell LLC is a global biotechnology company that explores therapeutic applications of unique, patented, ischemia-tolerant mesenchymal stem cells (itMSCs) manufactured under cGMP conditions. CardioCell is a subsidiary of Stemedica Cell Technologies Inc., a global biotechnology company that manufactures adult allogeneic stem cells. The company’s technology is based on more than 30 years of research and clinical experience conducted by scientists and physicians in the United States, Europe and the former Soviet Union. CardioCell therapies offer a unique, proprietary technology based on the expansion of cells in constant hypoxia, which provides critical benefits in terms of safety, efficacy and scalability. The company has an exclusive, worldwide license from Stemedica to explore therapeutic indications for unmet cardiovascular needs, such as acute myocardial infarction (AMI), chronic heart failure (CHF) and peripheral artery disease (PAD). For more information, visit www.stemcardiocell.com.
###